Published:March 09, 2023DOI:
      Figure thumbnail fx1
      Zobair M. Younossi, MD, MPH, Editor
      Epidemiologic data published in 2023 suggest that nonalcoholic fatty liver (NAFLD) and nonalcoholic steatohepatitis (NASH) affect around 30% and 5% of the world population and is on track to become the most common cause of cirrhosis and hepatocellular carcinoma (HCC), the most common cause for liver death, and the most common indication for liver transplantation. Driven by the global pandemic of obesity and type 2 diabetes, the global burden of NAFLD can be measured not only in clinical terms (liver mortality, cirrhosis, HCC) but also by its negative impact on patient-reported outcomes and the economic burden of the disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect